Home › Research › Drug development
Recent advances and ongoing challenges in diabetes prevention and control in China
Geng T, Yin X, Guo Y, Liu G, Pan A, Liao Y.. Innovation (Cambridge (Mass.)), 2025-08-21
Topic: Risk, prevention and care in population studies
Diabetes, particularly type 2 diabetes, poses a significant public health challenge globally, with an especially pronounced impact in China. The prevalence of diabetes in China has surged from 2.5% in 1994 to 13.0% in 2021, with projections indicating a continued upward trend. This review provides a comprehensive overview of the diabetes burden in China and underscores the urgent need for effective prevention and control measures. We examine the epidemiology of diabetes, highlighting the rising prevalence of prediabetes, type 1 and type 2 diabetes, youth-onset diabetes, and gestational diabetes mellitus, as well as diabetes-related complications, including both macrovascular and microvascular complications, and emerging conditions like cancer, infectious disease, fatty liver disease, and dementia. Key risk factors, including genetic susceptibility, obesity, dietary factors, and physical activity, are discussed, with particular attention to how these factors manifest differently in Chinese versus western populations. The review highlights advancements in national prevention efforts, innovative diabetes management models, and emerging technological innovations. The review also addresses advancements in pharmacological therapies, including the introduction of novel glucose-lowering agents such as GLP-1 receptor agonists, and SGLT2 inhibitors, which offer both metabolic and cardio-renal benefits. However, significant challenges remain, including the underrepresentation of the Chinese population in current research, persistent regional disparities, gaps in primary healthcare capacity, and the need for better integration of new technologies into clinical practice.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Geng, T., Yin, X., Guo, Y., Liu, G., Pan, A., & Liao, Y. (2026). Recent advances and ongoing challenges in diabetes prevention and control in China. Innovation (Cambridge (Mass.)). https://doi.org/10.1016/j.xinn.2025.101083
Vancouver
Geng T, Yin X, Guo Y, Liu G, Pan A, Liao Y. Recent advances and ongoing challenges in diabetes prevention and control in China. Innovation (Cambridge (Mass.)). 2026. doi:10.1016/j.xinn.2025.101083. PMID: 41737324.
BibTeX
@article{geng2026-41737324,
author = {Geng, T. and Yin, X. and Guo, Y. and Liu, G. and Pan, A. and Liao, Y.},
title = {{Recent advances and ongoing challenges in diabetes prevention and control in China}},
journal = {Innovation (Cambridge (Mass.))},
year = {2026},
doi = {10.1016/j.xinn.2025.101083},
pmid = {41737324},
url = {https://doi.org/10.1016/j.xinn.2025.101083}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Diabetes, particularly type 2 diabetes, poses a significant public health challenge globally, with an especially pronounced impact in China.
- Key risk factors, including genetic susceptibility, obesity, dietary factors, and physical activity, are discussed, with particular attention to how these factors manifest differently in Chinese versus western populations.
- However, significant challenges remain, including the underrepresentation of the Chinese population in current research, persistent regional disparities, gaps in primary healthcare capacity, and the need for better integration of new technologies into clinical practice.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Effect size2.5%; 13.0%
- Evidence strengthLow
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 29 of the 58 points we could judge it on, which is 50 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Innovation (Cambridge (Mass.))) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41737324) |
| Free to read | 2 / 2 | Free to read |
| Points | 29 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 29 of the 58 points we could judge it on is 50 out of 100. |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development
Also tagged “recent-advances”
4 studies in the library carry the topic tag “recent-advances”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.